Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.

Trial Profile

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2009

At a glance

  • Drugs Plozalizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Millennium
  • Most Recent Events

    • 20 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top